-

Definium Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

  • TD Cowen 46th Annual Health Care Conference
  • Jefferies Biotech on the Beach Summit
    • Date: Tuesday, March 10, 2026
    • Location: Miami Beach, FL
  • Leerink Partners Global Healthcare Conference
  • Stifel 2026 Virtual CNS Forum

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

Industry:

Definium Therapeutics, Inc.

NASDAQ:DFTX
Release Versions
English

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

More News From Definium Therapeutics, Inc.

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 28,640 common shares of the Company (the “Options”) with...

Definium Therapeutics Appoints Roger Adsett to Board of Directors

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. “We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful ma...
Back to Newsroom